A Phase II Study of NirAparib, Dostarlimab and Radiotherapy in Metastatic, PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR) TBCRC-055 20-649

Clinical Trial Grant

Duke Scholars

Principal Investigator Susan Faye Dent Medicine, Medical Oncology

Administered By

Duke Cancer Institute

Awarded By

GlaxoSmithKline

Start Date

September 5, 2024

End Date

March 31, 2028

Administered By

Duke Cancer Institute

Awarded By

GlaxoSmithKline

Start Date

September 5, 2024

End Date

March 31, 2028